On February 10, 2017, Anthera Pharmaceuticals, Inc. (“Anthera”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) informing Anthera that for the last 30 consecutive business days, the bid price of Anthera’s common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Nasdaq Listing Rule 5450(a)(1). The letter stated that Nasdaq will provide Anthera a grace period of 180 calendar days, or until August 9, 2017, to regain compliance. To regain compliance, any time before August 9, 2017, the bid price of Anthera’s common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days. The last reported sale price of Anthera’s common stock was $0.62 per share on February 10, 2017.

About ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH)

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Recent Trading Information

ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) closed its last trading session down -0.035 at 0.677 with 1,327,375 shares trading hands.